CA2186854A1 - Variantes d'interleukine humaine generees par epissage de remplacement - Google Patents

Variantes d'interleukine humaine generees par epissage de remplacement

Info

Publication number
CA2186854A1
CA2186854A1 CA002186854A CA2186854A CA2186854A1 CA 2186854 A1 CA2186854 A1 CA 2186854A1 CA 002186854 A CA002186854 A CA 002186854A CA 2186854 A CA2186854 A CA 2186854A CA 2186854 A1 CA2186854 A1 CA 2186854A1
Authority
CA
Canada
Prior art keywords
exon
human
seq
mrna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002186854A
Other languages
English (en)
Inventor
William J. Alms
Barbara White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2186854A1 publication Critical patent/CA2186854A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux mutants des interleukines 2 et 4 obtenus par épissage, ces mutants comportant les exons 1, 3 et 4 des ARNm pleine longueur, auxquels il manque cependant l'exon 2. Les protéines issues de l'expression de ces mutants obtenus par épissage sont utiles pour la régulation de l'activité des interleukines pleine longueur.
CA002186854A 1994-03-30 1995-03-30 Variantes d'interleukine humaine generees par epissage de remplacement Abandoned CA2186854A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21983194A 1994-03-30 1994-03-30
US08/219,831 1994-03-30
US22401094A 1994-04-06 1994-04-06
US08/224,010 1994-04-06

Publications (1)

Publication Number Publication Date
CA2186854A1 true CA2186854A1 (fr) 1995-10-12

Family

ID=26914296

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186854A Abandoned CA2186854A1 (fr) 1994-03-30 1995-03-30 Variantes d'interleukine humaine generees par epissage de remplacement

Country Status (5)

Country Link
EP (1) EP0775202A4 (fr)
JP (1) JPH09511400A (fr)
AU (1) AU2237395A (fr)
CA (1) CA2186854A1 (fr)
WO (1) WO1995027052A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666298A1 (fr) 1995-08-24 1997-03-06 Genaera Corporation Facteurs associes a l'asthme cibles pour traiter des allergies atopiques incluant l'asthme et des troubles connexes
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins

Also Published As

Publication number Publication date
EP0775202A1 (fr) 1997-05-28
AU2237395A (en) 1995-10-23
JPH09511400A (ja) 1997-11-18
EP0775202A4 (fr) 1999-07-14
WO1995027052A1 (fr) 1995-10-12

Similar Documents

Publication Publication Date Title
Gauchat et al. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production.
Bonifas et al. Epidermolysis bullosa simplex: evidence in two families for keratin gene abnormalities
Alms et al. Generation of a variant of human interleukin-4 by alternative splicing
Behrmann et al. Structure of the human APO‐1 gene
AU692196B2 (en) Translational enhancer DNA
Azuma et al. Cloning of cDNA for human T-cell replacing factor (interieukin-5) and comparison with the murine homologue
AU760224B2 (en) Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
EP0159714B1 (fr) Production de gamma-interféron
US7928073B2 (en) Purified polypeptides having IL-13 receptor activity
EP0977856B1 (fr) Variants de lag-3 obtenus par epissage
Nishimura et al. Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA
JP2021528105A (ja) インターロイキン−２バリアントおよびその使用方法
Hayes et al. Interferon-γ–dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the cpG-rich promoter active in epstein-barr virus-transformed lymphoblastoid cells
EP0851030B1 (fr) PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
CN112638938A (zh) 白介素12融合蛋白及其组合物和治疗方法
CA2186854A1 (fr) Variantes d'interleukine humaine generees par epissage de remplacement
WO1994028134A1 (fr) Facteur chimiotactique des lymphocytes et utilisations de celui-ci
Alberini et al. Differentiation in the murine B cell lymphoma I. 29: individual μ+ clones may be induced by lipopolysaccharide to both IgM secretion and isotype switching
WO2007149067A2 (fr) Procédés d'utilisation de phhla2 pour une stimulation conjointe des lymphocytes t
US5766943A (en) DNA sequences for soluble form of CD23
Kondo et al. Reduced expression of the interferon‐gamma messenger RNA in IgG2 deficiency
WO1995011040A1 (fr) Clonage de l'antigene du groupe sanguin de duffy
Paquette et al. An interferon-γ activation sequence mediates the transcriptional regulation of the IgG Fc receptor type IC gene by interferon-γ
Lorenz et al. Immunoglobulin class switching
AU697868C (en) The cloning of Duffy blood group antigen

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20000330